⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12476176 | 1.00 | — | — | |
| SCHEMBL12476566 | 1.00 | — | — | |
| SCHEMBL6853642 | 0.97 | — | — | |
| SCHEMBL14799413 | 0.75 | MEN1 (0.41) | — | |
| SCHEMBL14802925 | 0.75 | MEN1 (0.41) | — | |
| SCHEMBL9975308 | 0.74 | RAB9A (0.42) | — | |
| SCHEMBL9975293 | 0.72 | — | — | |
| SCHEMBL14799651 | 0.71 | MEN1 (0.43) | — | |
| SCHEMBL9622419 | 0.71 | — | — | |
| SCHEMBL14799652 | 0.71 | MEN1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021023843-A1 | IMPROVED SYNTHETIC METHODS OF MAKING (2H-1,2,3-TRIAZOL-2-YL)PHENYL COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-11 | — | — | WO | disclosed |
| US-9340520-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340520-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340520-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2673271-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-2673271-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-05-06 | — | — | EP | disclosed |
| CN-103347878-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-05-06 | — | — | CN | disclosed |
| US-20140012020-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140012020-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130028859-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130028859-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130028859-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| WO-2012109080-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012109080-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-16 | — | — | WO | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20100168129-A1 | DRUGS WITH ANTICHOLESTATIC ACTIVITY | FARMACEUTICI CABER S.P.A. (IT) | 2010-07-01 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |